Blog

Herbert Loong: The Role of Selective RET Inhibitors in the Management of NSCLC

Herbert Loong/LinkedIn

Jun 8, 2025, 08:38

Herbert Loong: The Role of Selective RET Inhibitors in the Management of NSCLC

Herbert Loong, Chair-Elect of the International Affairs Committee and the Track Leader for Sarcoma (2023) at the American Society of Clinical Oncology (ASCO), shared a post on LinkedIn:

“Ending a whirlwind trip to Manila Philippines to discuss with thoracic oncologists on the role of selective RET inhibitors in the management of NSCLC and the relevance and importance of efficient molecular testing.

Thanks Herdee Gloriane C. Luna, Roselle De Guzman and other Filipino colleagues for your wonderful hospitality and interactive discussions. :)”

Herbert Loong reflected on discussions held in Manila regarding selective RET inhibitors in NSCLC treatment and the critical role of effective molecular testing.

More posts featuring Herbert Loong.

American Society of Clinical Oncology ASCO cancer fight against cancer Global fight against cancer Herbert Loong Herdee Gloriane C. Luna molecular testing NSCLC OncoDaily Oncology RET inhibitors Roselle De Guzman

MiNK Therapeutics Stock Surges on Breakthrough Testicular Cancer Remission and iNKT Cell Therapy Progress

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Kevin Conroy: Oncodetect is Now Covered by Medicare in Stage IV Colorectal Cancer